Navigation Links
KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
Date:5/24/2011

NORTH LIBERTY, Iowa, May 24, 2011 /PRNewswire/ -- KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of its most advanced opioid-based drug candidate, KP201, a novel hydrocodone prodrug for treating pain.  KP201 is a new chemical entity (NCE) composed of hydrocodone chemically bound to a ligand.

The data confirmed that KP201 is cleaved in man as predicted, releasing the active pharmaceutical compound hydrocodone into the bloodstream at amounts equivalent to the reference listed drug (RLD), Norco®.  Importantly, intact KP201 could not be detected in systemic circulation, indicating that minimal additional studies are warranted to determine the impact of KP201 exposure in the body.

"Our findings from this first clinical trial of KP201 are as good as we could have hoped," stated Sven Guenther, Ph.D., Vice President of Research at KemPharm. "The human pharmacokinetic profile of KP201 indicates that the prodrug releases hydrocodone efficiently and is bioequivalent to the comparator drug, supporting a 505(b)(2) regulatory pathway for KP201 in combination with acetaminophen. KP201 has unique physiochemical and pharmacological attributes that deliver additional patient benefits, including reduced potential for abuse as well as reduction or elimination of opioid-induced constipation."

The Phase 1 study was a single dose, three-treatment, three-period, six-sequence, cross-over PK study in which twenty-four healthy volunteers received oral doses of 5 mg KP201, 10 mg KP201, or 10/325 mg tablet of hydrocodone bitartrate and acetaminophen (Norco®, RLD).  The objectives of the study included evaluation of the serum concentrations of hydrocodone, certain metabolites, and intact KP201, as well as safety and tolerability.

"We believe KP201 has the potential to assume sizeable market share, given the opportunity for extended market exclusivity in acute and chronic pain, as well as the potential to mi
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Companys ADHD Prodrug Technology
2. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology
3. KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  BC Technical, the nation,s leading non-OEM provider ... a leader in sales, service and installation of GE ... Technical to continue to expand their resources and inventory ... modalities. "We are committed to driving ... , president and CEO of BC Technical. "We set ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
(Date:8/29/2014)... Aug. 29, 2014   Vittamed Corporation , a neurodiagnostics ... announced today that T. (Teo) Forcht Dagi , MD, ... Board of Directors. " Teo Forcht Dagi ... neurosurgery, medical innovation and venture capital," said Remis Bistras ... to add his clinical, strategic, and entrepreneurial expertise to our ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... its preliminary unaudited sales range for the third quarter ... full year 2010. A conference call to discuss these ... on October 25, 2010 at 8:00 a.m. Eastern Time ...
... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
Cached Medicine Technology:Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 2Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 3Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 ... retrieve, organize and analyze biological and genetic data. ... the activity of developing software tools to generate ... to be confused with biological computation. While bioinformatics ... understanding of biology can its related concepts, biological ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on Tattoo ... members access to thousands of professionally designed tattoo images ... to help both people who plan on getting a ... for inspiration in creating one of a kind models. ... visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . , ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Pastor Thompson is ... Specialist at Eagle Village. He is a licensed minister through ... over the past twenty years in New Mexico, Colorado and ... years of marriage this year. He also has two ... a B.S. in Pastoral Ministry from Nazarene Bible College, in ...
Breaking Medicine News(10 mins):Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... experience have developed a weapon against one rapidly lethal war ... armor, where the trunk and legs join, to injure the ... within minutes. , "There is no way to ... in this area and dying within several minutes," said Dr. ...
... that previous models used to examine cancer may not ... environment. Using oral cancer cells in a three-dimensional model ... oral cavity, the researchers found that the tissue surrounding ... expression or suppression of a cell adhesion protein associated ...
... through hospital emergency departments and operated on within 48 ... by UK experts in anaesthesia, orthopaedics, geriatrics and emergency ... Anaesthesia . However, patients in one in ... than two days, risking lengthier inpatient stays, increased health ...
... Reporter , TUESDAY, Jan. 10 (HealthDay News) -- Unlike the ... declines in lung function that could lead to breathing problems, ... that road toward breathlessness, but low to moderate levels of ... there were limits to the study. For example, the findings ...
... sister with newly diagnosed cancer can be a distressing and ... there can be a period of adjustment when their school ... Central,s open access journal Child and Adolescent Psychiatry and ... improve the child,s knowledge about their sibling,s disease and to ...
... much more likely to develop mental health disorders as ... in clinical psychology at the University of Houston (UH) ... for Kids (SACK). To address this problem ... a clinical research center at UH that provides low-cost, ...
Cached Medicine News:Health News:Emergency medicine physicians develop device to stop lethal bleeding in soldiers 2Health News:Emergency medicine physicians develop device to stop lethal bleeding in soldiers 3Health News:Lab-made tissue picks up the slack of Petri dishes in cancer research 2Health News:Hip fracture guidelines tackle 'considerable variations' in UK and Irish hospital care 2Health News:Hip fracture guidelines tackle 'considerable variations' in UK and Irish hospital care 3Health News:Occasional Pot Smoking Won't Harm Lungs: Study 2Health News:Occasional Pot Smoking Won't Harm Lungs: Study 3Health News:New educational program helps the siblings of children with cancer 2Health News:University of Houston opens Sleep and Anxiety Center for Kids 2Health News:University of Houston opens Sleep and Anxiety Center for Kids 3
... Lyphochek Immunoassay Plus Control provides ... comprehensive control in the world for ... procedures, eliminating the need for separate ... no added preservatives, it is suitable ...
... Plus Control is a liquid ... today's busy immunoassay laboratory. With ... human serum based control can ... control products for immunoassay and ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Detection Platform provides fully automated detection of ... platform for molecular pathology labs separates DNA ... features that deliver a high degree of ... the capacity to run two 96-well plates, ...
Medicine Products: